Sacituzumab Govitecan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 747 publications

Use of sacituzumab govitecan in HR+/HER2- metastatic breast cancer following progression on endocrine therapy and chemotherapy: a case report in line with the results of the TROPiCS-02 study.

Use of sacituzumab govitecan in HR+/HER2- metastatic breast cancer following progression on endocrine therapy and chemotherapy: a case report in line with the results of the TROPiCS-02 study.

Journal: Recenti progressi in medicina

Published: September 02, 2026

Efficacy and safety of sacituzumab govitecan in patients with metastatic HR+/HER2- pleomorphic lobular breast cancer complicated by renal impairment.

Efficacy and safety of sacituzumab govitecan in patients with metastatic HR+/HER2- pleomorphic lobular breast cancer complicated by renal impairment.

Journal: Recenti progressi in medicina

Published: September 02, 2026

Sacituzumab govitecan in ER+/HER2- breast cancer: a necessary treatment option for patients who have undergone multiple prior treatments.

Sacituzumab govitecan in ER+/HER2- breast cancer: a necessary treatment option for patients who have undergone multiple prior treatments.

Journal: Recenti progressi in medicina

Published: September 02, 2026

Treatment-Related Toxicities of Antibody-Drug Conjugates in Breast Cancer: A Bayesian Network Meta-Analysis.

Treatment-Related Toxicities of Antibody-Drug Conjugates in Breast Cancer: A Bayesian Network Meta-Analysis.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: August 20, 2026

Antibody-drug conjugates in breast cancer: the first-line and curative setting.

Antibody-drug conjugates in breast cancer: the first-line and curative setting.

Journal: Current opinion in oncology

Published: August 14, 2026

Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple negative breast cancer CALGB40603 (Alliance).

Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple negative breast cancer CALGB40603 (Alliance).

Journal: The Journal of clinical investigation

Published: August 04, 2026

Efficacy and safety of TROP2 antibody-drug conjugate-containing regimen in the patients with HER2 negative metastatic breast cancer and advanced non-small-cell lung cancer.

Efficacy and safety of TROP2 antibody-drug conjugate-containing regimen in the patients with HER2 negative metastatic breast cancer and advanced non-small-cell lung cancer.

Journal: Journal of chemotherapy (Florence, Italy)

Published: July 29, 2026

Efficacy of sacituzumab govitecan in multi-treated metastatic breast cancer and clinical management of oligoprogressions.

Efficacy of sacituzumab govitecan in multi-treated metastatic breast cancer and clinical management of oligoprogressions.

Journal: Recenti progressi in medicina

Published: July 16, 2026

Long-term treatment with sacituzumab govitecan in a patient with brain metastases from triple-negative breast cancer, PD-L1-negative, BRCA1/2 wild-type.

Long-term treatment with sacituzumab govitecan in a patient with brain metastases from triple-negative breast cancer, PD-L1-negative, BRCA1/2 wild-type.

Journal: Recenti progressi in medicina

Published: July 16, 2026

Sustained clinical benefit with sacituzumab govitecan in metastatic triple-negative breast cancer with extensive cutaneous involvement.

Sustained clinical benefit with sacituzumab govitecan in metastatic triple-negative breast cancer with extensive cutaneous involvement.

Journal: Recenti progressi in medicina

Published: July 16, 2026

TROP-2 and Nectin-4 Expression in Muscle-Invasive Urothelial and Rare Non-Urothelial Bladder Carcinoma: Association with Tumour Stage and Clinical Outcome.

TROP-2 and Nectin-4 Expression in Muscle-Invasive Urothelial and Rare Non-Urothelial Bladder Carcinoma: Association with Tumour Stage and Clinical Outcome.

Journal: Cancers

Published: June 28, 2026

Brain metastases in triple-negative breast cancer: a systematic review of current trends, treatment strategies, and outcomes.

Brain metastases in triple-negative breast cancer: a systematic review of current trends, treatment strategies, and outcomes.

Journal: Journal of neuro-oncology

Published: June 19, 2026

Showing 1-12 of 747

Last Updated: 09/26/2026